Discussing and researching different treatments for hairloss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.
The conversation discusses various hairlosstreatments, including Minoxidil, finasteride, tretinoin, latanoprost, and GHK-Cu, with skepticism about expensive branded products like Zeus. Users suggest that similar results can be achieved with cheaper alternatives.
GT20029 shows promising results for hairlosstreatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
Considering treatments for hairloss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.
The conversation discusses the hairlosstreatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
The conversation discusses hairlosstreatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
People discussed starting hairlosstreatments like finasteride, dutasteride, and minoxidil due to personal experiences or comments about their hairloss. Some reported positive results, while others mentioned side effects or switching treatments.
The user's experience with Pyrilutamide for hairlosstreatment, including their belief that it has sparked improvements in combination with other treatments such as Minoxidil and Finasteride. Another user was also hoping to see results from using Pyrilutamide alone.
The conversation discusses hairlosstreatments like topical finasteride with minoxidil, oral dutasteride, and essential oils. Oral treatments like dutasteride and finasteride are seen as more effective, though some prefer topicals to avoid side effects.
The user successfully reduced hairloss using pumpkin seed oil, Nizoral shampoo, and astaxanthin without using minoxidil or finasteride. They observed significant improvement over 12 months and believe the combination of treatments is effective.
The user started a hairlosstreatment with a topical solution containing 0.1% Dutasteride, 7.5% Minoxidil, 0.0125% Tretinoin, and Biotin, along with a multivitamin, Ashwagandha, CBD oil, Retinol, and Caffeine Solution. They experienced some shedding and scalp irritation, leading to a reduction in the use of the caffeine solution.
PP405 is a new hairlosstreatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
The conversation is about hairlosstreatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
PP405 is a promising new hairlosstreatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
The conversation is about hairlosstreatments, focusing on the use of dutasteride, minoxidil, and microneedling. Users suggest adding minoxidil and microneedling for better results, while some caution against using RU58841 due to potential risks.
The conversation is about the comparison between finasteride and dutasteride for hairlosstreatment. The conclusion is that there is more fear around finasteride due to its higher prevalence and being the first line of defense, while dutasteride is less commonly prescribed and used by those who have already tried finasteride without side effects.
Hairlosstreatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.
Kintor's Pyrilutamide results for hairlosstreatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
Hairlosstreatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
The user regrets stopping finasteride and minoxidil due to increased hairloss. They have resumed these treatments and are considering a hair transplant.
Hair regrowth from treatments like finasteride, dutasteride, and minoxidil can take several years, with most visible results appearing within 1-2 years and potential improvements continuing up to 10 years. Consistency and patience are crucial for achieving maximum hair thickness, as hair miniaturization and regrowth are gradual processes.
PP405 is a potential new hairlosstreatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
PP405 and GT20029 are new hairlosstreatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
PP405 is a potential hairlosstreatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
The conversation discusses various hairlosstreatments, including minoxidil, finasteride, dutasteride, RU58841, microneedling, ketoconazole shampoo, and laser therapy. Users emphasize the importance of consistency, patience, and individual response to treatments.
RU58841 is discussed as a potential hairlosstreatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.